Download PDF
Thromb Haemost 1958; 02(01/02): 024-038
DOI: 10.1055/s-0038-1656262
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Stuart-Prower Factor Assay and its Clinical Significance[*]

F Bachmann
1   Coagulation laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier), University of Zurich, Switzerland
,
F Duckert
1   Coagulation laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier), University of Zurich, Switzerland
,
F Koller   **
1   Coagulation laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier), University of Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
07 June 2018 (online)

    Permissions and Reprints

Summary

A simple one-stage test for the determination of the Stuart-Prower factor is described. The method is a modification of the classical Factor VII complex assay, using a Russell’s viper venom (Stypven)-cephalin reagent instead of brain thromboplastin. The optimal conditions for the assay system have been systematically investigated. A high dilution of RVV (1 : 200 000) has given the best results. The system is not influenced by different concentrations of fibrinogen, prothrombin, Factor V, Factor VII and plasma thromboplastin precursors other than Stuart-Prower factor. Variations of lipoid and/or platelet contents of the plasma do not alter the results. Stuart-Prower factor is not activated by glass contact. The method has proved most valuable in the detection of heterozygous Stuart-Prower factor deficiencies. Comparison with a specific Stuart-Prower factor assay using patient’s plasma deficient in Stuart-Prower factor gave variations not greater than 15%. If determined simultaneously with the Quick one-stage ‘prothrombin time’, the test may provide a better control of patients under treatment with dicoumarol derivatives.

* This study was aided by grants from the ‘Emil Barell-Foundation for Medical Research.’


** With the technical assistance of Miss D. Gerber.


 

  • References

  • 1 Ackroyd J. F. The function of factor VII. Brit. J. Haemat. 2: 397 1956;
    CrossrefPubMedGoogle Scholar
  • 2 Bachmann F, Duckert F, Flückiger P, Hitzig W, und Koller F. Über einen neuartigen kongenitalen Gerinnungsdefekt (Mangel an Stuart-Faktor). Thromb. Diath. haem. 1: 87 1957;
    PubMedGoogle Scholar
  • 3 Bachmann F, Duckert F, Geiger M, Baer P, and Koller F. Differentiation of the factor VII complex. Studies on the Stuart-Prower factor. Thromb. Diath. haem. 1: 169 1957;
    PubMedGoogle Scholar
  • 4 Bachmann F, Duckert F, Flückiger P, und Hitzig W. H. Hämorrhagische Diathesen verursacht durch Mangel des Stuart-Prower-Faktors. Schweiz. Med. Wschr. 87: 1221 1957;
    PubMedGoogle Scholar
  • 5 Bachmann F, Duckert F, and Koller F. Stuart-Prower factor deficiencies. VIth Congr. Europ. Soc. Haemat. Copenhagen. In press
    PubMed
  • 6 Biggs R. Some observations on the blood of patients with ‘Factor VIF deficiency. Brit. J. Haemat. 2: 412 1956;
    CrossrefPubMedGoogle Scholar
  • 7 Flückiger P, Hitzig W. H, Bachmann F, und Duckert F. Hämorrhagische Diathese, bedingt durch kongenitalen Mangel eines neuen Gerinnungsfaktors (Prower-Stuart-Faktor). Helv. Paed. Acta 12: 260 1957;
    PubMedGoogle Scholar
  • 8 Fullerton W. H. Estimation of prothrombin. Lancet 2: 195 1940;
    PubMedGoogle Scholar
  • 9 Geiger M, Duckert F, und Koller F. Quantitative Bestimmungen von Faktor VIII und IX bei Blutersippen. Vth Congr. Europ. Soc. Haemat. Freiburg. p. 413 1955
    PubMed
  • 10 Graham J. B, and Hougie C. The Stuartfactor (Hypoproconvertinemia?). The clotting defect and mode of inheritance. Vlth Congr. Int. Soc. Haemat. Boston, p. 327 1956
    PubMed
  • 11 Graham J. B, Barrow E, and Hougie C. Stuart clotting defect. II. Genetic aspects of a ‘new’ hemorrhagic state. J. Clin. Invest. 36: 497 1957;
    CrossrefPubMedGoogle Scholar
  • 12 Hicks N. D. A coagulation disorder due to a Factor VII-like defect. Med. J. Austr. 2: 331 1955;
    PubMedGoogle Scholar
  • 13 Hjort P, Rapaport S. I, and Owren P. A. A simple specific one-stage prothrombin assay using Russell’s Viper Venom in cephalin suspension. J. Lab. Clin. Med. 46: 89 1955;
    PubMedGoogle Scholar
  • 14 Hougie C, and Graham J. B. The blood clotting role and mode of inheritance of the Stuart Factor. Vlth Congr. Int. Soc. Blood Transf. Boston, p. 80 1956
    PubMed
  • 15 Hougie C. The role of Russell’s Viper Venom on the Stuart clotting defect. Proc. Soc. exp. Biol. 93: 570 1956;
    CrossrefPubMedGoogle Scholar
  • 16 Hougie C, Barrow E, and Graham J. B. Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called ‘Stable Factor’ (SPCA, Proconvertin, Factor VII) deficiency. J. Clin. Invest. 36: 485 1957;
    CrossrefPubMedGoogle Scholar
  • 17 Jenkins J. S. The thromboplastic activity of Russell’s Viper Venom and its relationship to factor VII. J. clin. Path. 7: 287 1954;
    CrossrefPubMedGoogle Scholar
  • 18 Koller F, Loeliger A, and Duckert F. Experiments on a new clotting factor (Factor VII). Acta Haemat. 6: 1 1951;
    CrossrefPubMedGoogle Scholar
  • 19 Milstone J. H. The problem of the lipid thromboplastins. Yale J. Biol. Med. 22: 675 1950;
    PubMedGoogle Scholar
  • 20 Owren P. A. Inactive Proconvertin, active Proconvertin and Convertin. Rev. Hémat. 10: 350 1955;
    PubMedGoogle Scholar
  • 21 Rapaport S. L, Aas K, and Owren P. A. The coagulant activity of Russell’s Viper Venom. Scand. J. Clin. Lab. Invest. 6: 81 1954;
    CrossrefPubMedGoogle Scholar
  • 22 Rapaport S. I, Aas K, and Owren P. A. The clotting action of Russell’s Viper Venom. Blood 9: 1185 1954;
    PubMedGoogle Scholar
  • 23 Rapaport S. I, Aas K, and Owren P. A. The effect of glass upon the activity of the various plasma clotting factors. J. Clin. Invest. 34: 9 1955;
    CrossrefPubMedGoogle Scholar